Patents by Inventor Tino Dyhring
Tino Dyhring has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11396510Abstract: The present invention relates to 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol, which is useful as a GABA receptor modulator. In one embodiment, said compound is useful in the treatment of pain, neuropathic pain and/or itch.Type: GrantFiled: September 13, 2019Date of Patent: July 26, 2022Assignee: Saniona A/SInventors: Janus S. Larsen, Dipak Amrutkar, Thomas Amos Jacobsen, Tino Dyhring, Karin Sandager Nielsen
-
Publication number: 20220143014Abstract: The present invention relates to a subtype selective partial agonist of ?6 containing nicotinic acetylcholine receptors. Due to its uniquely selective and functional profile, 9-methyl-3-pyridin-3-yl-3,9-diaza-bicyclo[3.3.1]nonane may be useful in the treatment, prevention and/or alleviation of a disease, disorder and/or condition which is responsive to activation of a nicotinic acetylcholine receptor (nAChR) in a subject, wherein the nAChR comprises at least one cholinergic receptor nicotinic alpha 6 subunit (nAChR?6). Preferably, said disease, disorder and/or condition is a Parkinsonian disorder or pain.Type: ApplicationFiled: December 1, 2020Publication date: May 12, 2022Inventors: Tino Dyhring, Dan Peters, Palle Christophersen, Karin Sandager Nielsen, Lars Ulrik Wahlberg, Dipak Amrutkar
-
Publication number: 20210332042Abstract: The present invention relates to 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H- imidazo[4,5-b]pyridin-6-yl)propan-2-ol, which is useful as a GABA receptor modulator. In one embodiment, said compound is useful in the treatment of pain, neuropathic pain and/or itch.Type: ApplicationFiled: September 13, 2019Publication date: October 28, 2021Inventors: Janus S. LARSEN, Dipak AMRUTKAR, Thomas Amos JACOBSEN, Tino DYHRING, Karin Sandager NIELSEN
-
Publication number: 20180311238Abstract: The present invention relates to a subtype selective partial agonist of ?6 containing nicotinic acetylcholine receptors. Due to its uniquely selective and functional profile, 9-methyl-3-pyridin-3-yl-3,9-diaza-bicyclo[3.3.1]nonane may be useful in the treatment, prevention and/or alleviation of a disease, disorder and/or condition which is responsive to activation of a nicotinic acetylcholine receptor (nAChR) in a subject, wherein the nAChR comprises at least one cholinergic receptor nicotinic alpha 6 subunit (nAChRa6). Preferably, said disease, disorder and/or condition is a Parkinsonian disorder or pain.Type: ApplicationFiled: April 27, 2018Publication date: November 1, 2018Inventors: Tino Dyhring, Dan Peters, Palle Christophersen, Karin Sandager Nielsen, Lars Ulrik Wahlberg, Dipak Amrutkar
-
Patent number: 8946412Abstract: This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Ar1 represents a pyrrolyl group, optionally substituted with alkyl or halo-alkyl.Type: GrantFiled: December 16, 2010Date of Patent: February 3, 2015Assignee: Danpet ABInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Tino Dyhring, Philip K. Ahring
-
Patent number: 8778928Abstract: This invention relates to novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: January 25, 2010Date of Patent: July 15, 2014Assignee: Danpet ABInventors: Dan Peters, Daniel B. Timmermann, Tino Dyhring, Jeppe Kejser Christensen, Elsebet Østergaard Nielsen
-
Patent number: 8372832Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: March 14, 2012Date of Patent: February 12, 2013Assignee: Neurosearch A/SInventors: Dan Peters, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jens Damsgaard Mikkelsen, Henrik Björk Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Tino Dyhring
-
Publication number: 20130004428Abstract: This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Ar1 represents a pyrrolyl group, optionally substituted with alkyl or halo-alkyl.Type: ApplicationFiled: December 16, 2010Publication date: January 3, 2013Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Tino Dyhring, Philip K. Ahring
-
Patent number: 8343960Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: November 13, 2008Date of Patent: January 1, 2013Assignee: Neurosearch A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Ostergaard Nielsen, Gunnar M. Olsen, Tino Dyhring, Jeppe Kejser Christensen, John Paul Redrobe, Jens Damsgaard Mikkelsen
-
Publication number: 20120309792Abstract: This invention relates to novel tetrazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: December 16, 2010Publication date: December 6, 2012Applicant: NEUROSEARCH A/SInventors: Dan Peters, Morten Grunnet, Daniel B. Timmermann, Birgitte L. Eriksen, Tino Dyhring, Philip K. Ahring
-
Publication number: 20120238553Abstract: This invention relates to novel benzodioxolyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances (I).Type: ApplicationFiled: January 25, 2010Publication date: September 20, 2012Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Tino Dyhring, Jeppe Kejser Christensen
-
Patent number: 8236793Abstract: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: December 8, 2009Date of Patent: August 7, 2012Assignee: Neurosearch A/SInventors: Dan Peters, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Tino Dyhring Jørgensen, Daniel B Timmermann
-
Publication number: 20120172353Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: March 14, 2012Publication date: July 5, 2012Inventors: Dan PETERS, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jens Damsgaard Mikkelsen, Henrik Björk Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Tino Dyhring
-
Patent number: 8173658Abstract: This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: December 5, 2006Date of Patent: May 8, 2012Assignee: Neurosearch A/SInventors: Dan Peters, Daniel B. Timmermann, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Tino Dyhring
-
Patent number: 8158619Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: May 29, 2007Date of Patent: April 17, 2012Assignee: Neurosearch A/SInventors: Dan Peters, Gunnar M. Olsen, Elsebet ØStergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jen Damsgaard Mikkelsen, Henrik Björk Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Tino Dyhring
-
Publication number: 20120071469Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.1]octane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: May 12, 2010Publication date: March 22, 2012Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Jeppe Kejser Christensen, Tino Dyhring
-
Patent number: 8110588Abstract: This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: August 6, 2008Date of Patent: February 7, 2012Assignee: Neurosearch A/SInventors: Antonio Nardi, Jeppe Kejser Christensen, Dan Peters, Gunnar M. Olsen, Tino Dyhring
-
Publication number: 20120028967Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: January 20, 2010Publication date: February 2, 2012Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Tino Dyhring, Jeppe Kejser Christensen
-
Publication number: 20120028968Abstract: This invention relates to novel dibenzofuranyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: January 25, 2010Publication date: February 2, 2012Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Jeppe Kejser Christensen, Tino Dyhring
-
Patent number: 8101649Abstract: This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: November 19, 2008Date of Patent: January 24, 2012Assignee: Neurosearch A/SInventors: Antonio Nardi, Jeppe Kejser Christensen, Dan Peters, Tino Dyhring